undamentalytics Newsletter

Chemours Co income statement

In fiscal 2025, Chemours Co reported revenue of $5.81bn, up 0.4% on the year before and net income of −$386m, or −$2.57 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Chemours Co: income statement, annual
Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue6,8596,4325,7175,4006,1836,6385,5264,9696,3456,8316,0785,7825,8085,796
Cost of revenue———4,2974,4384,6674,4633,9024,9645,2154,7764,6404,9064,910
Gross profit1,4641,3609551,1031,7451,9711,0631,0671,3811,6161,3021,142902887
Research and development164143978181828093107118108109108106
Selling, general and administrative7686856329466266575485275927101,286598799868
Interest expense00132219214195208210185163208263269273
Net interest income——−132−219−214−195−208———————
Income before tax576550−188−119121,155−124179676741−318106−277−52
Income tax152149−98−18165159−72−4068163−6637109253
Net income423400−907746995−52219608578−25369−386−304
Diluted EPS$2.34$2.21−$0.50$0.04$3.91$5.45−$0.32$1.32$3.60$3.65−$1.70$0.46−$2.57−$2.02
Diluted shares (average)181m181m181m183m191m183m165m166m169m158m149m150m150m151m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CC vs OLNCC vs MEOHCC vs TROXCC vs WLK

More: Commodity Chemicals stocks compared, Materials sector, rankings of US companies

Figures from Chemours Co's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Chemours Co.